1 results match your criteria: "University of Arizona Health Science Center and Southern Arizona VA Health Care System[Affiliation]"
Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Aliment Pharmacol Ther
June 2009
Section of Gastroenterology, University of Arizona Health Science Center and Southern Arizona VA Health Care System, Tucson, AZ 85723, USA.
Background: The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis.
Aim: To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual Delayed Release technology, in NERD patients.
Methods: In this 4-week, double-blind, placebo-controlled study, 947 NERD patients randomly received dexlansoprazole MR 30 mg, 60 mg or placebo once daily (QD).